|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
NMDA receptor antagonist
|
|
gptkbp:brand
|
gptkb:Gocovri
|
|
gptkbp:class
|
Antiviral
|
|
gptkbp:clinical_trial
|
Phase 3
Management of Parkinson's disease symptoms
Reduction of dyskinesia
|
|
gptkbp:contraindication
|
Hypersensitivity to amantadine
|
|
gptkbp:dosage_form
|
gptkb:beer
|
|
gptkbp:duration
|
As prescribed by a physician
|
|
gptkbp:formulation
|
Extended-release capsule
|
|
gptkbp:has_ability
|
137 mg
204 mg
68.5 mg
|
|
gptkbp:healthcare
|
gptkb:2017
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gocovri
|
|
gptkbp:ingredients
|
Amantadine
|
|
gptkbp:interacts_with
|
Alcohol
CNS depressants
Hydrochlorothiazide
|
|
gptkbp:is_monitored_by
|
Monitor for psychiatric symptoms
|
|
gptkbp:is_used_for
|
gptkb:psychologist
Dyskinesia
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:manufacturer
|
Adamas Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:United_States
|
|
gptkbp:packaging
|
Blister pack
|
|
gptkbp:population
|
Adults
|
|
gptkbp:previous_name
|
Amantadine hydrochloride
|
|
gptkbp:provides_information_on
|
Follow neurologist recommendations
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:safety_features
|
Regular follow-up required
|
|
gptkbp:side_effect
|
gptkb:Insomnia
gptkb:Nausea
Dizziness
Dry mouth
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:type_of_care
|
Important for efficacy
|
|
gptkbp:bfsParent
|
gptkb:amantadine
|
|
gptkbp:bfsLayer
|
6
|